Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Medicine Lab, |
RCV001375989 | SCV001572990 | likely pathogenic | Non-immune hydrops fetalis | 2020-06-04 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001780276 | SCV002024608 | pathogenic | not provided | 2023-06-28 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001780276 | SCV002049306 | likely pathogenic | not provided | 2021-07-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001780276 | SCV002246019 | pathogenic | not provided | 2021-06-07 | criteria provided, single submitter | clinical testing | Experimental studies have shown that this variant affects PIEZO1 protein function (PMID:28619848, 30887001, 31091145). For these reasons, this variant has been classified as Pathogenic. This variant has been observed in individual(s) with hereditary xerocytosis (PMID: 28619848, 31624108, 30655378, 30887001). ClinVar contains an entry for this variant (Variation ID: 1065463). This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with methionine at codon 598 of the PIEZO1 protein (p.Val598Met). The valine residue is moderately conserved and there is a small physicochemical difference between valine and methionine. |
Mayo Clinic Laboratories, |
RCV001780276 | SCV002573758 | likely pathogenic | not provided | 2021-12-06 | criteria provided, single submitter | clinical testing | BP4, PM2, PS3, PS4_moderate |